FindTrial
Sign In

GM1

DRUG4 trials

Sponsors

Fudan University, Yuhong Li, Qilu Pharmaceutical Co., Ltd.

Conditions

Cerebral Radiation NecrosisChemotherapy-induced NeutropeniaChemotherapy-induced Peripheral Neuropathy (CIPN)Colorectal CancerMRINasopharyngeal CarcinomaParkinson's DiseaseRadiotherapy

Phase 2

A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations
Not yet recruitingNCT07585565
Qilu Pharmaceutical Co., Ltd.Parkinson's Disease
Start: 2026-05-01End: 2028-08-01Target: 276Updated: 2026-05-13

Phase 3

Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
CompletedNCT02251977
Yuhong LiChemotherapy-induced Neutropenia, Colorectal Cancer
Start: 2014-09-30End: 2017-09-05Updated: 2019-10-07
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
RecruitingNCT06994507
Qilu Pharmaceutical Co., Ltd.Chemotherapy-induced Peripheral Neuropathy (CIPN)
Start: 2025-08-01End: 2027-06-30Target: 352Updated: 2025-08-06

Unknown Phase

Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study
NCT01884987
Fudan UniversityCerebral Radiation Necrosis, MRI, Nasopharyngeal Carcinoma +1
Start: 2012-01-31End: 2014-12-31Target: 30Updated: 2014-01-07

Related Papers

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
Cancer Medicine2019-11-1323 citations
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.
Journal of Clinical Oncology2019-01-29